Suppression of p38α MAPK Signaling in Osteoblast Lineage Cells Impairs Bone Anabolic Action of Parathyroid Hormone

Journal of Bone and Mineral Research

Volumn 31, Issue 5, 2016, Pages 985-993

  Thouverey, Cyril ^a   Caverzasio, Joseph ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

BONE ANABOLISM; BONE REMODELING; OSTEOBLASTS; p38 MAPK; PARATHYROID HORMONE

Indexed keywords

CRE RECOMBINASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; SOMATOMEDIN C; MITOGEN ACTIVATED PROTEIN KINASE P38; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE METABOLISM; CELL ACTIVITY; CELL COUNT; CELL LINEAGE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE INACTIVATION; HORMONE ACTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENE; UPREGULATION; ANIMAL; DRUG EFFECTS; GENETICS; MAPK SIGNALING; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARATHYROID HORMONE; RANK LIGAND;

EID: 84968752808     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2762     Document Type: Article

References (34)

1. Huang JC, Sakata T, Pfleger LL, et al., PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004; 19 (2): 235-44.
2. Saini V, Marengi DA, Barry KJ, et al., Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem. 2013; 288 (28): 20122-34.
3. Jilka RL., Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40 (6): 1434-46.
4. Kousteni S, Bilezikian JP., The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep. 2008; 6 (2): 72-6.
5. Qin L, Raggatt LJ, Partridge NC., Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15 (2): 60-5.
6. Neer RM, Arnaud CD, Zanchetta JR, et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434-41.
7. Baron R, Hesse E., Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012; 97 (2): 311-25.
8. Hodsman AB, Bauer DC, Dempster DW, et al., Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005; 26 (5): 688-703.
9. Kim SW, Pajevic PD, Selig M, et al., Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res. 2012; 27 (10): 2075-84.
10. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC., Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104 (4): 439-46.
11. Kramer I, Loots GG, Studer A, Keller H, Kneissel M., Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25 (2): 178-89.
12. Bedi B, Li JY, Tawfeek H, et al., Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci USA. 2012; 109 (12): E725-33.
13. Datta NS, Abou-Samra AB., PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009; 21 (8): 1245-54.
14. Zhang R, Edwards JR, Ko SY, et al., Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts. PLoS One. 2011; 6 (6): e20780.
15. Wang Y, Nishida S, Boudignon BM, et al., IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res. 2007; 22 (9): 1329-37.
16. Bikle DD, Wang Y., Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone. Curr Mol Pharmacol. 2012; 5 (2): 135-42.
17. Fermor B, Skerry TM., PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res. 1995; 10 (12): 1935-43.
18. Armamento-Villareal R, Ziambaras K, Abbasi-Jarhomi SH, et al., An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats. J Bone Miner Res. 1997; 12 (3): 384-92.
19. Rey A, Manen D, Rizzoli R, Caverzasio J, Ferrari SL., Proline-rich motifs in the parathyroid hormone (PTH)/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1/2 activation. J Biol Chem. 2006; 281 (50): 38181-8.
20. Rey A, Manen D, Rizzoli R, Ferrari SL, Caverzasio J., Evidences for a role of p38 MAP kinase in the stimulation of alkaline phosphatase and matrix mineralization induced by parathyroid hormone in osteoblastic cells. Bone. 2007; 41 (1): 59-67.
21. Bianchi EN, Ferrari SL., Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts. Bone. 2009; 45 (4): 716-25.
22. Greenblatt MB, Shim JH, Zou W, et al., The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest. 2010; 120 (7): 2457-73.
23. Thouverey C, Caverzasio J., The p38alpha MAPK positively regulates osteoblast function and postnatal bone acquisition. Cell Mol Life Sci. 2012; 69 (18): 3115-25.
24. Rodriguez-Carballo E, Gamez B, Sedo-Cabezon L, et al., The p38alpha MAPK function in osteoprecursors is required for bone formation and bone homeostasis in adult mice. PLoS One. 2014; 9 (7): e102032.
25. Heinrichsdorff J, Luedde T, Perdiguero E, Nebreda AR, Pasparakis M., p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep. 2008; 9 (10): 1048-54.
26. Zhang M, Xuan S, Bouxsein ML, et al., Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002; 277 (46): 44005-12.
27. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
28. Dempster DW, Compston JE, Drezner MK, et al., Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28 (1): 2-17.
29. Chen C, Koh AJ, Datta NS, et al., Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem. 2004; 279 (28): 29121-9.
30. Bellido T, Ali AA, Plotkin LI, et al., Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278 (50): 50259-72.
31. Pierroz DD, Bonnet N, Baldock PA, et al., Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem. 2010; 285 (36): 28164-73.
32. Qin L, Qiu P, Wang L, et al., Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem. 2003; 278 (22): 19723-31.
33. Zarubin T, Han J., Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005; 15 (1): 11-8.
34. Whitehouse CA, Waters S, Marchbank K, et al., Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of postnatal osteoblastic bone formation and p38 MAPK activity. Proc Natl Acad Sci USA. 2010; 107 (29): 12913-8.